n-acetyl-2-phenylethylamine, also known as N-acetylphenethylamine or NAPA, is a naturally occurring trace amine found in the human brain. It is a derivative of phenethylamine, a stimulant that acts as a releasing agent for monoamine neurotransmitters, including dopamine, norepinephrine, and serotonin. NAPA is thought to have a variety of potential pharmacological effects, including antidepressant, anxiolytic, and nootropic properties. However, its precise mechanisms of action and therapeutic potential are still under investigation. NAPA is also known to be a substrate for the enzyme monoamine oxidase (MAO), which breaks down neurotransmitters. Its significance lies in its potential for therapeutic application, particularly in treating depression and anxiety. Research into NAPA continues to explore its possible role in modulating neurotransmitter function and its potential benefits for mental health.'
| ID Source | ID |
|---|---|
| PubMed CID | 70143 |
| CHEMBL ID | 99827 |
| CHEBI ID | 18177 |
| SCHEMBL ID | 7858 |
| MeSH ID | M0153818 |
| Synonym |
|---|
| CHEMBL99827 |
| n-phenethyl-acetamide |
| BB 0263213 |
| F0020-1761 |
| acetamide, n-phenethyl- |
| n-(2-phenylethyl)acetamide |
| acetamide, n-(2-phenylethyl)- |
| n-phenethylacetamide |
| nsc-7177 |
| nsc7177 |
| n-beta-phenylethylacetamide |
| CHEBI:18177 , |
| n-acetylphenethylamine |
| einecs 212-897-8 |
| nsc 7177 |
| brn 2208721 |
| MEGXM0_000495 |
| STK364324 |
| 877-95-2 |
| n-(2-phenylethyl)-acetamide |
| n-acetylphenylethylamine , |
| n-acetyl-2-phenylethylamine |
| C06746 |
| AKOS003082304 |
| n-(2-phenethyl)acetamide |
| P1066 |
| unii-2jxy218szi |
| 2jxy218szi , |
| FT-0629790 |
| n-(.beta.-phenylethyl)acetamide |
| n-2-phenethylacetamide |
| GS-0407 |
| AB00172777-03 |
| n-acetyl-phenethylamine |
| acetylphenethylamine |
| n-acetyl (2-phenyl)ethylamine |
| acetamide,n-(2-phenylethyl)- |
| SCHEMBL7858 |
| SY007035 |
| n-(phenethyl)acetamide |
| mfcd00026177 |
| n-(2-phenethyl)-acetamide |
| (2-phenethyl)acetamide |
| AS-871/40170832 |
| 54w , |
| n-(ss-phenylethyl)acetamide |
| DTXSID50236574 |
| n-acetylphenethylamide |
| NCGC00332267-01 |
| glipizide impurity 1 |
| Q27102876 |
| A862412 |
| n-(2-phenylethyl)acetamide (en) |
| Z27761567 |
| Class | Description |
|---|---|
| N-acetyl-2-arylethylamine | An acetamide compound of general formula RCH2CH2NHC(=O)CH3 where R represents an aryl moiety. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID107544 | Tested for binding affinity to compete for 2-[125I]iodomelatonin binding to chicken retinal membranes; NE- No effect | 1993 | Journal of medicinal chemistry, Oct-01, Volume: 36, Issue:20 | 2-Amido-8-methoxytetralins: a series of nonindolic melatonin-like agents. |
| AID165367 | Tested for in vitro inhibition of calcium-dependent release of [3H]-dopamine from rabbit retina; ND-Not determined | 1993 | Journal of medicinal chemistry, Oct-01, Volume: 36, Issue:20 | 2-Amido-8-methoxytetralins: a series of nonindolic melatonin-like agents. |
| AID1134000 | Inhibition of chymotrypsin (unknown origin) | 1977 | Journal of medicinal chemistry, Apr, Volume: 20, Issue:4 | Quantitative structure-activity relationships of chymotrypsin. On the predictive value of correlation equations. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 3 (50.00) | 18.7374 |
| 1990's | 2 (33.33) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.23) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 6 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||